• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在库欣病患者接受帕西瑞肽治疗后监测患者改善参数

Monitoring Patient Improvement Parameters following Pasireotide Treatment in Cushing's Disease.

作者信息

Yedinak Chris, Brzana Jessica, Fleseriu Maria

机构信息

Northwest Pituitary Center, 3303 SW Bond Avenue, Portland, OR 97239, USA ; Department of Neurosurgery, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.

出版信息

Case Rep Endocrinol. 2013;2013:735489. doi: 10.1155/2013/735489. Epub 2013 Oct 31.

DOI:10.1155/2013/735489
PMID:24288633
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3833195/
Abstract

Cushing's disease (CD) is a disorder in which chronic excess adrenocorticotropic hormone production is associated with multiple comorbidities and diminished quality of life. Postsurgical monitoring is important, and newer therapies are available for the management of surgical failure or disease recurrence. In this clinical case, we illustrate the importance of the nursing role in long-term management of CD, particularly as nurses may be the first point of contact for patients with CD. Alertness to disease signs and symptoms is crucial for timely diagnosis and improved outcomes. Successful therapy for CD requires careful monitoring of hormonal control, metabolic parameters, and therapy complications. Ongoing management requires lifelong monitoring of metabolic parameters, of side effects of treatment, and of signs of disease recurrence. Appropriate referrals may be required to facilitate overall outcomes and patient wellbeing. This patient was enrolled in a Phase III trial that was registered in the USA with clinicaltrial.gov.

摘要

库欣病(CD)是一种慢性促肾上腺皮质激素分泌过多并伴有多种合并症及生活质量下降的疾病。术后监测很重要,并且有新的疗法可用于治疗手术失败或疾病复发。在本临床病例中,我们阐述了护理在库欣病长期管理中的重要作用,特别是因为护士可能是库欣病患者的首个接触点。对疾病体征和症状保持警觉对于及时诊断和改善预后至关重要。库欣病的成功治疗需要仔细监测激素控制、代谢参数和治疗并发症。持续管理需要对代谢参数、治疗副作用和疾病复发迹象进行终身监测。可能需要进行适当的转诊以促进整体预后和患者健康。该患者参加了一项在美国clinicaltrial.gov注册的III期试验。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bca5/3833195/2a9e47b28354/CRIM.ENDOCRINOLOGY2013-735489.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bca5/3833195/fe7d34b740e4/CRIM.ENDOCRINOLOGY2013-735489.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bca5/3833195/327bdb973807/CRIM.ENDOCRINOLOGY2013-735489.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bca5/3833195/9a8953550e54/CRIM.ENDOCRINOLOGY2013-735489.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bca5/3833195/2a9e47b28354/CRIM.ENDOCRINOLOGY2013-735489.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bca5/3833195/fe7d34b740e4/CRIM.ENDOCRINOLOGY2013-735489.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bca5/3833195/327bdb973807/CRIM.ENDOCRINOLOGY2013-735489.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bca5/3833195/9a8953550e54/CRIM.ENDOCRINOLOGY2013-735489.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bca5/3833195/2a9e47b28354/CRIM.ENDOCRINOLOGY2013-735489.004.jpg

相似文献

1
Monitoring Patient Improvement Parameters following Pasireotide Treatment in Cushing's Disease.在库欣病患者接受帕西瑞肽治疗后监测患者改善参数
Case Rep Endocrinol. 2013;2013:735489. doi: 10.1155/2013/735489. Epub 2013 Oct 31.
2
Cushing's disease: current medical therapies and molecular insights guiding future therapies.库欣病:当前的医学治疗方法及指导未来治疗的分子见解。
Neurosurg Focus. 2015 Feb;38(2):E11. doi: 10.3171/2014.10.FOCUS14700.
3
The treatment with pasireotide in Cushing's disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center.帕瑞肽治疗库欣病:单中心经验中,长期治疗对临床特征和代谢特征的影响及不良反应的处理。
J Endocrinol Invest. 2020 Jan;43(1):57-73. doi: 10.1007/s40618-019-01077-8. Epub 2019 Jul 16.
4
Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial.每月一次帕瑞肽治疗库欣病的疗效和安全性:为期 12 个月的临床试验。
Lancet Diabetes Endocrinol. 2018 Jan;6(1):17-26. doi: 10.1016/S2213-8587(17)30326-1. Epub 2017 Oct 12.
5
Pasireotide (SOM230): a novel pituitary-targeted medical therapy for the treatment of patients with Cushing's disease.帕西瑞肽(SOM230):一种用于治疗库欣病患者的新型垂体靶向药物疗法。
Expert Rev Endocrinol Metab. 2012 Sep;7(5):491-502. doi: 10.1586/eem.12.49.
6
Long-term medical treatment of cushing's disease with pasireotide: a review of current evidence and clinical experience.帕瑞肽用于库欣病的长期药物治疗:当前证据及临床经验综述
Exp Clin Endocrinol Diabetes. 2014 Sep;122(8):445-50. doi: 10.1055/s-0034-1376988. Epub 2014 Jul 8.
7
Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials.库欣病的治疗:当前和近期临床试验概述。
Front Endocrinol (Lausanne). 2020 Dec 8;11:648. doi: 10.3389/fendo.2020.00648. eCollection 2020.
8
Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial.帕西瑞肽长期治疗库欣病:一项III期试验开放标签扩展研究的5年结果
Endocrine. 2017 Jul;57(1):156-165. doi: 10.1007/s12020-017-1316-3. Epub 2017 Jun 9.
9
Medical treatment of Cushing's disease: somatostatin analogues and pasireotide.库欣病的治疗:生长抑素类似物和帕瑞肽。
Neuroendocrinology. 2010;92 Suppl 1:120-4. doi: 10.1159/000314352. Epub 2010 Sep 10.
10
Budget impact of pasireotide for the treatment of Cushing's disease, a rare endocrine disorder associated with considerable comorbidities.用于治疗库欣病的培高利特的预算影响,库欣病是一种罕见的内分泌疾病,与相当多的合并症相关。
J Med Econ. 2014 Apr;17(4):288-95. doi: 10.3111/13696998.2013.877470. Epub 2014 Mar 11.

引用本文的文献

1
The treatment with pasireotide in Cushing's disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center.帕瑞肽治疗库欣病:单中心经验中,长期治疗对临床特征和代谢特征的影响及不良反应的处理。
J Endocrinol Invest. 2020 Jan;43(1):57-73. doi: 10.1007/s40618-019-01077-8. Epub 2019 Jul 16.
2
Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial.帕西瑞肽长期治疗库欣病:一项III期试验开放标签扩展研究的5年结果
Endocrine. 2017 Jul;57(1):156-165. doi: 10.1007/s12020-017-1316-3. Epub 2017 Jun 9.
3

本文引用的文献

1
The burden of Cushing's disease: clinical and health-related quality of life aspects.库欣病的负担:临床和与健康相关的生活质量方面。
Eur J Endocrinol. 2012 Sep;167(3):311-26. doi: 10.1530/EJE-11-1095. Epub 2012 Jun 22.
2
Medical management of Cushing's disease: what is the future?库欣病的医学治疗:未来如何?
Pituitary. 2012 Sep;15(3):330-41. doi: 10.1007/s11102-012-0397-5.
3
Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome.米非司酮,一种糖皮质激素受体拮抗剂,可给库欣综合征患者带来临床和代谢获益。
Medical Therapy with Pasireotide in Recurrent Cushing's Disease: Experience of Patients Treated for At Least 1 Year at a Single Center.
帕西瑞肽治疗复发性库欣病的药物治疗:单中心至少治疗1年患者的经验
Front Endocrinol (Lausanne). 2017 Feb 27;8:35. doi: 10.3389/fendo.2017.00035. eCollection 2017.
4
The Treatment of Cushing's Disease.库欣病的治疗
Endocr Rev. 2015 Aug;36(4):385-486. doi: 10.1210/er.2013-1048. Epub 2015 Jun 11.
5
The treatment with pasireotide in Cushing's disease: effects of long-term treatment on tumor mass in the experience of a single center.帕瑞肽治疗库欣病:单中心经验中长期治疗对肿瘤体积的影响
Endocrine. 2015 Dec;50(3):725-40. doi: 10.1007/s12020-015-0557-2. Epub 2015 Mar 6.
6
Up-to 5-year efficacy of pasireotide in a patient with Cushing's disease and pre-existing diabetes: literature review and clinical practice considerations.帕西瑞肽治疗库欣病合并糖尿病患者长达5年的疗效:文献综述与临床实践考量
Pituitary. 2015 Jun;18(3):359-65. doi: 10.1007/s11102-014-0582-9.
J Clin Endocrinol Metab. 2012 Jun;97(6):2039-49. doi: 10.1210/jc.2011-3350. Epub 2012 Mar 30.
4
A 12-month phase 3 study of pasireotide in Cushing's disease.一项为期 12 个月的培塞利肽治疗库欣病的 3 期研究。
N Engl J Med. 2012 Mar 8;366(10):914-24. doi: 10.1056/NEJMoa1105743.
5
Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease.酮康唑再探讨:库欣病的术前或术后治疗
Eur J Endocrinol. 2008 Jan;158(1):91-9. doi: 10.1530/EJE-07-0514.
6
Late recurrences of Cushing's disease after initial successful transsphenoidal surgery.库欣病初次经蝶窦手术成功后出现的晚期复发
J Clin Endocrinol Metab. 2008 Feb;93(2):358-62. doi: 10.1210/jc.2007-2013. Epub 2007 Dec 4.
7
Cushing's syndrome.库欣综合征
Lancet. 2006 May 13;367(9522):1605-17. doi: 10.1016/S0140-6736(06)68699-6.
8
Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance.库欣病垂体手术后的长期缓解率:长期监测的必要性。
Clin Endocrinol (Oxf). 2005 Nov;63(5):549-59. doi: 10.1111/j.1365-2265.2005.02380.x.
9
Diagnosis and complications of Cushing's syndrome: a consensus statement.库欣综合征的诊断与并发症:一项共识声明。
J Clin Endocrinol Metab. 2003 Dec;88(12):5593-602. doi: 10.1210/jc.2003-030871.
10
Medical therapy of Cushing's disease.库欣病的医学治疗
Pituitary. 2002;5(2):77-82. doi: 10.1023/a:1022308429992.